Speaker
Description
Most radiopharmaceuticals are used for the purpose of
medical diagnosis. These radiopharmaceuticals contain
small amount of the active substances with a
radionuclide attached to them to allow scintigraphic
imaging or measurement of biodistribution. Radiation is
a general property of all radiopharmaceuticals, which
when administered give the patient an imminent
radiation dose. Quality control (QC) tests are mandatory
for radioactive drugs which are intended for human
administration [1]. The safety and efficacy of
radiopharmaceuticals are important factor of the quality
assurance protocol. QA in radiopharmacy is critical for
practice. A poor-quality diagnostic radiopharmaceutical,
while not in itself unsafe, it could give incorrect
information about the patient’s condition leading to an
inappropriate choice of therapy [2]
In this study a considerable number of DMSA, PYP,
MAG-3, DTPA and HMPAO radiopharmaceuticals
samples are analyzed for their radiochemical purity using
radiochemical purity standard procedure. These products
used in nuclear medicine Department of University
Hospital Centre “Mother Theresa” and some private
clinics in Albania are collected and tested for 5 years
period. The aim of the work is to present the results for
their radiochemical purity and to emphasize the need for
the radiopharmaceutical quality control. The mean
radiochemical purity was 96.94% (standard deviation
7.82%) and 4.52% of all tested preparations failed to
meet radiochemical preparation limits.
Most radiopharmaceutical kits are prepared using
